Home' Australian Pharmacist : Australian Pharmacist Sept 2013 Contents Australian Pharmacist September 2013 I ©Pharmaceutical Society of Australia Ltd. 75
BUSINESS AND INDUSTRY NEWS
NPSA warns on direct
Reliable access to vital medicines will be
threatened if others in the industry move
to an exclusive direct distribution model,
the National Pharmaceutical Services
Association (NPSA) has warned.
The warning followed the release of a
PricewaterhouseCoopers report, Issues
and decisions: A report on the Australian
pharmaceutical industry, found that 31% of
pharmaceutical companies surveyed were
considering a direct distribution model.
The NPSA Referred a the Deloitte Access
Economics Report: Economic analysis
of exclusive distribution of PBS medicines
which has warned that further moves
by manufacturers to sideline the full-line
wholesalers will erode the viability of the
Community Service Obligation (CSO).
The Deloitte Report concludes that if more
manufacturers become the sole suppliers of
their medicines, pharmacists will be further
restricted to single, potentially unreliable
sources for the supply of PBS medicines.
NPSA President Patrick Davies said
legislative action is required to protect the
CSO, the National Medicines Policy and the
principle of equity of access that underpins
Australia's healthcare system.
'Pharmacies need more than one source of
supply and they need to be able to access
all PBS medicines from their full-line CSO
wholesaler -- otherwise patient care is
compromised,' Mr Davies said.
'Australia is a vast country with a small
population and specialist pharmaceutical
wholesaling depends on economies of
scale that are lost if the large pharma
companies pull out of the supply chain.
"Our healthcare system is the envy of
much of the world and we must act to
defend it by ensuring the exclusive supply
of PBS medicines is prevented as part of
negotiations around the Sixth Community
Gold Cross partners with
The Pharmacy Guild of Australia's (PGA)
Gold Cross brand has announced a new
partnership with a new range of Gold
Cross branded products set to appear
The Gold Cross-branded products,
endorsed by PGA, will appear on pharmacy
shelves shortly after the establishment
of a new endorsement partnership with
Listed pharmaceutical manufacturer,
marketer and distributor Probiotec
Limited will produce a range of cold
and flu, analgesic and other medicinal
products under the Gold Cross brand from
The new partnership follows a decision
by current Gold Cross logo partner Aspen
Australia and its Chemists' Own brand
to change strategy and not renew their
current endorsement agreement.
PGA National President Kos Sclavos said the
new partnership was a milestone for the
Guild's Gold Cross brand.
'Our partnership with Probiotec marks the
launch of the first exclusive Gold Cross-
branded range of products, as they will
be the only products in the cold, flu and
analgesic categories to be endorsed by the
Pharmacy Guild of Australia.
'The Guild's Gold Cross logo has long been
valued as an endorsement for the products
on which it appears, and we believe the
brand will continue to be a trusted choice
for both pharmacists and consumers alike.
'The Guild has enjoyed a longstanding
relationship with Aspen and we will
continue to maintain that relationship into
the future, on a range of other projects,
Mr Sclavos said.
Reviewing antipsychotic use
in aged care
NPS MedicineWise and Webstercare have
collaborated to add a new function to
Webstercare Medication Management
Software (MMS) to assist in reviewing
antipsychotic medicine use in residential
aged care facilities.
The new functionality allows pharmacists
to produce a report on the use of
antipsychotic medicines in each
residential aged care facility for which
they supply medicines. The new reporting
mechanism will enable pharmacists to
provide information to staff working in
residential aged care facilities and aid
them in understanding, analysing and
effectively managing the appropriate use of
antipsychotic medicines for their residents.
NPS MedicineWise CEO Dr Lynn Weekes AM
said evidence suggests there is extensive
off label use of antipsychotics for dementia
patients in residential aged care.
'While they can occasionally be effective
for short term aggression and psychotic
symptoms, we see them being used too
often, for too long at high doses and in
'Incorrect use of these medicines can
have serious consequences including an
increased risk of falls, hip fractures and even
death,' she said.
Dr Weekes said that the new, in-depth
quality use of medicines (QUM) report
in the Webstercare software provides
staff with objective measurements that
enable them to establish a baseline and
identify patterns of use over time, and even
compare their antipsychotic medicine use
with published studies.
'By partnering with Webstercare on
this project, we hope to ensure a more
appropriate use of antipsychotics in
residential aged care facilities in the
Webstercare CEO Mr Gerard Stevens
AM said that NPS MedicineWise and
Webstercare are committed to supporting
the aged care industry in its endeavour
to ensure the safe use of antipsychotics
and to improve care in line with
'The QUM report identifies residents who
may benefit from a medicine review from
'It will provide valuable data for the
local Medicine Advisory Committees in
residential aged care facilities to review
at their regular meetings. The residential
aged care facilities that were part of the
pilot program received it very positively,
saying that the report has the capability of
changing practice,' he said.
Mr Stevens said the report could also help
a residential aged care facility meet the
Accreditation Standards for Residential
Aged Care in areas such as continuous
improvement, medication management
and behavioural management. The QUM
reports are available as part of pharmacies'
latest software update of Webstercare's
Professional and Professional Plus
Medication Management Software (MMS).
Links Archive Australian Pharmacist August 2013 Australian Pharmacist Oct 2013 Navigation Previous Page Next Page